Botanix Releases Quarterly Reports

/in , , , /by

Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.